Evidence map›Paper›PMID 35489289›Full record

ArticleMolecular immunology2022

Regulation of IFNα-induced expression of the short ACE2 isoform by ULK1.

Ricardo E Perez, Diana Saleiro, Liliana Ilut, Gary E Schiltz, Frank Eckerdt, Eleanor N Fish, Leonidas C Platanias

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ricardo E PerezRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Diana SaleiroRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: diana.saleiro@northwestern.edu.
Liliana IlutRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Gary E SchiltzRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Department of Chemistry, Northwestern University, Evanston, IL, USA; Department of Pharmacology, Northwestern University, Chicago, IL, USA.
Frank EckerdtRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Eleanor N FishToronto General Hospital Research Institute, University Health Network and Department of Immunology, University of Toronto, Toronto, ON, Canada.
Leonidas C PlataniasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA. Electronic address: l-platanias@northwestern.edu.
Northwestern University · USNeurological Surgery · USToronto General Hospital · CA

Funding

Signal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6M
TRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7M
Development of Novel MNK Inhibitors for Treating GlioblastomaR01NS113425 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C., SCHILTZ, GARY E · 2019 to 2023
$2.5M
A Novel ULK1 Pathway as a New Therapeutic Target in MelanomaR21CA245447 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NORA VAZ SALEIRO, DIANA · 2020 to 2020
$409k
Signaling Pathways and Therapeutic Targeting of Leukemic CellsI01CX000916 · VA · JESSE BROWN VA MEDICAL CENTER · PI PLATANIAS, LEONIDAS C. · 2013 to 2025
–
CSRD VA I01 CX000916NCI NIH HHS R01 CA077816NCI NIH HHS R21 CA245447NCI NIH HHS T32 CA070085NINDS NIH HHS R01 NS113425
6 · The paper itself

Abstract

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to hijack angiotensin converting enzyme 2 (ACE2) for entry into mammalian cells. A short isoform of ACE2, termed deltaACE2 (dACE2), has recently been identified. In contrast to ACE2, the short dACE2 isoform lacks the ability to bind the spike protein of SARS-CoV-2. Several studies have proposed that expression of ACE2 and/or dACE2 is induced by interferons (IFNs). Here, we report that drug-targeted inhibition or silencing of Unc51-like kinase 1 (ULK1) results in repression of type I IFN-induced expression of the dACE2 isoform. Notably, dACE2 is expressed in various squamous tumors. In efforts to identify pharmacological agents that target this pathway, we found that fisetin, a natural flavonoid, is an ULK1 inhibitor that decreases type I IFN-induced dACE2 expression. Taken together, our results establish a requirement for ULK1 in the regulation of type I IFN-induced transcription of dACE2 and raise the possibility of clinical translational applications of fisetin as a novel ULK1 inhibitor.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19AnimalsInterferon-alphaMammalsProtein IsoformsSARS-CoV-2Angiotensin-Converting Enzyme 2Interferon-alphaProtein IsoformsACE2DeltaACE2FisetinInterferonShort ACE2ULK1

Identifiers

PMID35489289
PMCPMC9045748
OpenAlexW4224989770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.